 Lisa Abuogi
Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 52 | 2026 | 3017 | 8.360 |
Why?
| | Anti-HIV Agents | 24 | 2025 | 859 | 6.220 |
Why?
| | Infectious Disease Transmission, Vertical | 24 | 2026 | 186 | 5.650 |
Why?
| | Kenya | 34 | 2025 | 123 | 4.000 |
Why?
| | Pregnancy Complications, Infectious | 13 | 2025 | 406 | 3.100 |
Why?
| | Breast Feeding | 9 | 2026 | 444 | 2.230 |
Why?
| | Anti-Retroviral Agents | 9 | 2024 | 245 | 2.090 |
Why?
| | Viral Load | 11 | 2025 | 506 | 1.680 |
Why?
| | Sexual Partners | 7 | 2023 | 189 | 1.670 |
Why?
| | Medication Adherence | 7 | 2025 | 513 | 1.390 |
Why?
| | Text Messaging | 4 | 2023 | 179 | 1.370 |
Why?
| | Pregnancy | 28 | 2026 | 7070 | 1.330 |
Why?
| | Qualitative Research | 7 | 2024 | 1516 | 1.280 |
Why?
| | Intimate Partner Violence | 3 | 2021 | 91 | 1.200 |
Why?
| | Infant | 28 | 2025 | 9818 | 1.150 |
Why?
| | Mothers | 7 | 2022 | 785 | 1.110 |
Why?
| | Peripartum Period | 2 | 2024 | 22 | 1.050 |
Why?
| | Social Support | 5 | 2024 | 633 | 1.030 |
Why?
| | HIV-1 | 3 | 2025 | 895 | 1.010 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2025 | 239 | 0.970 |
Why?
| | Social Stigma | 8 | 2026 | 145 | 0.960 |
Why?
| | Spouses | 4 | 2020 | 108 | 0.930 |
Why?
| | Prenatal Care | 4 | 2020 | 303 | 0.920 |
Why?
| | Focus Groups | 4 | 2024 | 565 | 0.900 |
Why?
| | Female | 50 | 2026 | 75515 | 0.810 |
Why?
| | Fathers | 1 | 2023 | 51 | 0.800 |
Why?
| | Peer Group | 2 | 2024 | 247 | 0.770 |
Why?
| | Patient Navigation | 1 | 2024 | 98 | 0.760 |
Why?
| | Postpartum Period | 7 | 2025 | 353 | 0.750 |
Why?
| | Zambia | 5 | 2025 | 57 | 0.730 |
Why?
| | Young Adult | 20 | 2026 | 13673 | 0.730 |
Why?
| | Interviews as Topic | 3 | 2024 | 844 | 0.700 |
Why?
| | Fertilization | 1 | 2021 | 44 | 0.680 |
Why?
| | Humans | 58 | 2026 | 141187 | 0.650 |
Why?
| | Mentors | 3 | 2021 | 210 | 0.640 |
Why?
| | Sustained Virologic Response | 1 | 2018 | 45 | 0.570 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 287 | 0.560 |
Why?
| | Adolescent | 20 | 2025 | 22007 | 0.540 |
Why?
| | Adult | 27 | 2026 | 39177 | 0.540 |
Why?
| | Motivation | 1 | 2022 | 602 | 0.540 |
Why?
| | Health Facilities | 2 | 2021 | 85 | 0.540 |
Why?
| | Telemedicine | 2 | 2025 | 891 | 0.530 |
Why?
| | Health Facility Administration | 1 | 2017 | 7 | 0.530 |
Why?
| | Community Health Services | 2 | 2019 | 233 | 0.520 |
Why?
| | Spouse Abuse | 1 | 2017 | 42 | 0.510 |
Why?
| | Truth Disclosure | 1 | 2017 | 53 | 0.510 |
Why?
| | Male | 29 | 2026 | 69783 | 0.500 |
Why?
| | Reminder Systems | 1 | 2018 | 174 | 0.480 |
Why?
| | Patient Dropouts | 1 | 2016 | 65 | 0.480 |
Why?
| | Infant, Newborn | 10 | 2024 | 6275 | 0.470 |
Why?
| | Child | 21 | 2025 | 22308 | 0.460 |
Why?
| | Health Resources | 1 | 2016 | 129 | 0.450 |
Why?
| | Drug Resistance, Viral | 2 | 2025 | 120 | 0.410 |
Why?
| | Tuberculosis | 2 | 2014 | 285 | 0.410 |
Why?
| | Point-of-Care Systems | 3 | 2023 | 185 | 0.380 |
Why?
| | Treatment Failure | 3 | 2025 | 354 | 0.380 |
Why?
| | Health Knowledge, Attitudes, Practice | 5 | 2026 | 1396 | 0.380 |
Why?
| | Patient Compliance | 1 | 2016 | 610 | 0.360 |
Why?
| | Colorado | 4 | 2025 | 4610 | 0.320 |
Why?
| | Prospective Studies | 5 | 2025 | 7739 | 0.320 |
Why?
| | Patient Acceptance of Health Care | 3 | 2025 | 878 | 0.320 |
Why?
| | Consultants | 2 | 2026 | 13 | 0.300 |
Why?
| | Child, Preschool | 9 | 2025 | 11457 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2025 | 1556 | 0.270 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1597 | 0.260 |
Why?
| | Lactation | 2 | 2026 | 192 | 0.260 |
Why?
| | Developing Countries | 2 | 2021 | 317 | 0.250 |
Why?
| | Case-Control Studies | 3 | 2018 | 3588 | 0.230 |
Why?
| | Cross-Sectional Studies | 6 | 2026 | 5636 | 0.220 |
Why?
| | Retrospective Studies | 8 | 2024 | 16273 | 0.210 |
Why?
| | United States | 5 | 2026 | 15220 | 0.210 |
Why?
| | Intention | 1 | 2025 | 178 | 0.210 |
Why?
| | Risk Factors | 5 | 2025 | 10438 | 0.200 |
Why?
| | Infant Health | 1 | 2023 | 24 | 0.200 |
Why?
| | Dried Blood Spot Testing | 1 | 2024 | 121 | 0.200 |
Why?
| | RNA, Viral | 2 | 2024 | 693 | 0.200 |
Why?
| | Maternal Health | 1 | 2023 | 52 | 0.200 |
Why?
| | Prevalence | 3 | 2024 | 2772 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2024 | 1261 | 0.190 |
Why?
| | CD4 Lymphocyte Count | 2 | 2024 | 284 | 0.190 |
Why?
| | DNA, Viral | 1 | 2024 | 366 | 0.190 |
Why?
| | Drug Resistance | 1 | 2022 | 150 | 0.180 |
Why?
| | Telephone | 1 | 2023 | 182 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2025 | 1018 | 0.180 |
Why?
| | Sexual Behavior | 1 | 2025 | 497 | 0.170 |
Why?
| | Emigrants and Immigrants | 1 | 2023 | 149 | 0.170 |
Why?
| | Treatment Outcome | 5 | 2021 | 11120 | 0.170 |
Why?
| | Treatment Adherence and Compliance | 1 | 2021 | 27 | 0.170 |
Why?
| | Organophosphates | 1 | 2022 | 156 | 0.170 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 36 | 0.170 |
Why?
| | Public Health Surveillance | 1 | 2021 | 84 | 0.170 |
Why?
| | Transition to Adult Care | 1 | 2022 | 92 | 0.160 |
Why?
| | Mass Screening | 2 | 2020 | 1310 | 0.160 |
Why?
| | Reward | 1 | 2022 | 256 | 0.160 |
Why?
| | Pilot Projects | 1 | 2025 | 1820 | 0.160 |
Why?
| | Symptom Assessment | 1 | 2021 | 129 | 0.160 |
Why?
| | Infant, Low Birth Weight | 1 | 2021 | 146 | 0.160 |
Why?
| | Students | 1 | 2025 | 645 | 0.160 |
Why?
| | Patient Participation | 1 | 2023 | 432 | 0.160 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2021 | 235 | 0.160 |
Why?
| | Adenine | 1 | 2022 | 301 | 0.150 |
Why?
| | Health Personnel | 2 | 2023 | 737 | 0.150 |
Why?
| | Disclosure | 1 | 2019 | 112 | 0.150 |
Why?
| | C-Reactive Protein | 1 | 2021 | 418 | 0.150 |
Why?
| | Hospitals | 1 | 2023 | 696 | 0.140 |
Why?
| | Ambulatory Care | 1 | 2023 | 582 | 0.140 |
Why?
| | Odds Ratio | 1 | 2021 | 1052 | 0.140 |
Why?
| | Emotions | 1 | 2023 | 575 | 0.140 |
Why?
| | Pregnancy Outcome | 1 | 2021 | 457 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 110 | 0.140 |
Why?
| | Self Disclosure | 1 | 2017 | 65 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2026 | 5929 | 0.130 |
Why?
| | HIV | 1 | 2018 | 250 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1143 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 633 | 0.130 |
Why?
| | Multicenter Studies as Topic | 1 | 2018 | 338 | 0.130 |
Why?
| | Decision Making | 1 | 2024 | 961 | 0.120 |
Why?
| | HIV Seropositivity | 1 | 2017 | 127 | 0.120 |
Why?
| | Comorbidity | 1 | 2021 | 1662 | 0.120 |
Why?
| | Marriage | 1 | 2017 | 123 | 0.120 |
Why?
| | Rural Population | 2 | 2017 | 604 | 0.120 |
Why?
| | Logistic Models | 2 | 2025 | 2086 | 0.110 |
Why?
| | Hospitalization | 2 | 2023 | 2255 | 0.110 |
Why?
| | Health Services Research | 1 | 2017 | 406 | 0.110 |
Why?
| | Attitude of Health Personnel | 2 | 2024 | 1171 | 0.100 |
Why?
| | Isoniazid | 1 | 2014 | 61 | 0.100 |
Why?
| | Biomarkers | 2 | 2024 | 4174 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2892 | 0.100 |
Why?
| | Cohort Studies | 3 | 2024 | 5799 | 0.100 |
Why?
| | Incidence | 2 | 2022 | 2794 | 0.090 |
Why?
| | Antitubercular Agents | 1 | 2014 | 207 | 0.090 |
Why?
| | Nasopharynx | 2 | 2022 | 74 | 0.090 |
Why?
| | Mutation | 1 | 2022 | 4013 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 961 | 0.090 |
Why?
| | Depression | 1 | 2020 | 1483 | 0.080 |
Why?
| | Prognosis | 1 | 2018 | 4073 | 0.080 |
Why?
| | Time Factors | 1 | 2018 | 6956 | 0.060 |
Why?
| | Oxazines | 1 | 2025 | 32 | 0.060 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2025 | 36 | 0.060 |
Why?
| | Risk Assessment | 2 | 2025 | 3490 | 0.060 |
Why?
| | Canada | 1 | 2026 | 428 | 0.050 |
Why?
| | Observation | 1 | 2024 | 56 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 176 | 0.050 |
Why?
| | Cerebrospinal Fluid | 1 | 2024 | 92 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 586 | 0.050 |
Why?
| | Piperazines | 1 | 2025 | 354 | 0.050 |
Why?
| | Universities | 1 | 2025 | 452 | 0.050 |
Why?
| | North America | 1 | 2023 | 306 | 0.050 |
Why?
| | Point-of-Care Testing | 1 | 2022 | 35 | 0.050 |
Why?
| | Milk, Human | 1 | 2023 | 169 | 0.040 |
Why?
| | Africa, Northern | 1 | 2021 | 4 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2022 | 173 | 0.040 |
Why?
| | Oropharynx | 1 | 2020 | 45 | 0.040 |
Why?
| | Professional-Patient Relations | 1 | 2022 | 150 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1859 | 0.040 |
Why?
| | Trust | 1 | 2022 | 146 | 0.040 |
Why?
| | Income | 1 | 2021 | 201 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 194 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 403 | 0.040 |
Why?
| | Family Characteristics | 1 | 2020 | 192 | 0.040 |
Why?
| | Mental Health | 1 | 2025 | 749 | 0.040 |
Why?
| | House Calls | 1 | 2019 | 144 | 0.030 |
Why?
| | Gene Expression | 1 | 2022 | 1491 | 0.030 |
Why?
| | Delivery, Obstetric | 1 | 2018 | 163 | 0.030 |
Why?
| | Poverty | 1 | 2021 | 530 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2020 | 531 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1653 | 0.030 |
Why?
| | Program Evaluation | 1 | 2017 | 928 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3348 | 0.020 |
Why?
| | Middle Aged | 2 | 2026 | 34434 | 0.020 |
Why?
| | Aged | 1 | 2022 | 24574 | 0.010 |
Why?
|
|
Abuogi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|